

# Chapter 198

## Cutaneous Manifestations of Human Immunodeficiency Virus Disease

Lily Changchien Uihlein, Arturo Saavedra, & Richard Allen Johnson

### REFERENCES

1. AIDS Epidemic Update: *November 2009*. Geneva, Joint United Nations Programme on HIV/AIDS-World Health Organization, 2009, pp. 6-7
2. Hall HI et al: Estimation of HIV incidence in the United States. *JAMA* **300**(5):520-529, 2008
3. HIV Prevalence Estimates – United States, 2006. *MMWR* **57**(39):1073-1076, 2006
4. Rico MJ, Myers SA, Sanchez MR: Guidelines of care for dermatologic conditions in patients infected with HIV. Guidelines/Outcomes Committee. American Academy of Dermatology. *J Am Acad Dermatol* **37**(3 Pt 1):450-472, 1997
5. Calista D et al: Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. *Am J Clin Dermatol* **3**(1):59-62, 2002
6. Kanki PJ et al: Slower heterosexual spread of HIV-2 than HIV-1. *Lancet* **343**(8903):943-946, 1994
7. Gottlieb GS et al: Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resource-limited West Africa. *Clin Infect Dis* **48**(4):476-483, 2009
8. Marlink R et al: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. *Science* **265**(5178):1587-1590, 1994
9. Fauci AS, Lane HC: Human Immunodeficiency Virus Disease: AIDS and Related Disorders. In: *Harrison's Principles of Internal Medicine*, Vol. 1. 17th edition, edited by AS Fauci, E Braunwald, DL Kasper et al. New York, McGraw Hill Medical, 2008, pp. 1138-1204
10. Vanhems P et al: Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. *J Acquir Immune Defic Syndr* **21**(2):99-106, 1999
11. Kahn JO, Walker BD: Acute human immunodeficiency virus type 1 infection. *N Engl J Med* **339**(1):33-39, 1998
12. Rosenberg ES, Caliendo AM, Walker BD: Acute HIV infection among patients tested for mononucleosis. *N Engl J Med* **340**(12):969, 1999
13. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children: World Health Organization, 2006, 1-17
14. 1993 Revised Classification system for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults. *MMWR* **41**(RR-17), 1992
15. Berger RS et al: Cutaneous manifestations of early human immunodeficiency virus exposure. *J Am Acad Dermatol* **19**(2 Pt 1):298-303, 1988
16. Rajendran PM et al: Eosinophilic folliculitis: Before and after the introduction of antiretroviral therapy. *Arch Dermatol* **141**(10):1227-1231, 2005
17. Boonchai W et al: Pruritic papular eruption in HIV seropositive patients: A cutaneous marker for immunosuppression. *Int J Dermatol* **38**(5):348-350, 1999
18. Jung AC, Paauw DS: Diagnosing HIV-related disease: Using the CD4 count as a guide. *J Gen Intern Med* **13**(2):131-136, 1998
19. Libraty DH, Byrd TF: Cutaneous miliary tuberculosis in the AIDS era: Case report and review. *Clin Infect Dis* **23**(4):706-710, 1996
20. Nnoruka EN, Chukwuka JC, Anisuibia B: Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. *Int J Dermatol* **46**(Suppl. 2):14-18, 2007
21. Lortholary O et al: Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. *Am J Med* **95**(2):177-187, 1993
22. Koopman RJ et al: Molluscum contagiosum; a marker for advanced HIV infection. *Br J Dermatol* **126**(5):528-529, 1992

23. Lapins J et al: Mucocutaneous manifestations in 22 consecutive cases of primary HIV-1 infection. *Br J Dermatol* **134**(2):257-261, 1996
24. Shelburne SA, Montes M, Hamill RJ: Immune reconstitution inflammatory syndrome: More answers, more questions. *J Antimicrob Chemother* **57**(2):167-170, 2006
25. Shelburne SA et al: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. *AIDS* **19**(4):399-406, 2005
26. French MA et al: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. *HIV Med* **1**(2):107-115, 2000
27. Murdoch DM et al: Immune reconstitution inflammatory syndrome (IRIS): Review of common infectious manifestations and treatment options. *AIDS Res Ther* **4**:9, 2007
28. Chamberlain AJ et al: Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: a manifestation of immune restoration. *J Am Acad Dermatol* **51**(5 Suppl):S161-S165, 2004
29. Bachmeyer C et al: Multiple eruptive dermatofibromas after highly active antiretroviral therapy. *Br J Dermatol* **143**(6):1336-1337, 2000
30. Borrás-Blasco J et al: Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *J Antimicrob Chemother* **62**(5):879-888, 2008
31. Kong HH, Myers SA: Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. *Dermatol Ther* **18**(1):58-66, 2005
32. Luther J, Glesby MJ: Dermatologic adverse effects of antiretroviral therapy: recognition and management. *Am J Clin Dermatol* **8**(4):221-233, 2007
33. Lehloeny R, Meintjes G: Dermatologic manifestations of the immune reconstitution inflammatory syndrome. *Dermatol Clin* **24**(4):549-570, vii, 2006
34. Mathes BM, Douglass MC: Seborrhic dermatitis in patients with acquired immunodeficiency syndrome. *J Am Acad Dermatol* **13**(6):947-951, 1985
35. Menon K et al: Psoriasis in patients with HIV infection: From the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**(2):291-299, 2010
36. Mamkin I, Mamkin A, Ramanan SV: HIV-associated psoriasis. *Lancet Infect Dis* **7**(7):496, 2007
37. Greenspan D et al: Effect of highly active antiretroviral therapy on frequency of oral warts. *Lancet* **357**(9266):1411-1412, 2001
38. Meys R, Gotch FM, Bunker CB: Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: An immune reconstitution-associated disease? *Br J Dermatol* **162**(1):6-11, 2010
39. Maurer T et al: The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women. *Clin Infect Dis* **38**(4):579-584, 2004
40. Kojic EM, Cu-Uvin S: Update: Human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. *Curr Opin Oncol* **19**(5):464-469, 2007
41. Palefsky JM et al: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. *AIDS* **19**(13):1407-1414, 2005
42. Haas N et al: Remission of epidermodysplasia verruciformis-like skin eruption after highly active antiretroviral therapy in a human immunodeficiency virus-positive patient. *Br J Dermatol* **145**(4):669-670, 2001
43. McKenzie ND et al: Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. *Gynecol Oncol* **116**(3):572-577, 2010
44. Saiag P et al: Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: An open-label, non-comparative study. *Br J Dermatol* **161**(4):904-909, 2009
45. Sanclemente G et al: Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. *J Eur Acad Dermatol Venereol* **21**(8):1054-1060, 2007
46. Goldie SJ et al: The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA* **281**(19):1822-1829, 1999
47. Chiao EY et al: Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review. *Clin Infect Dis* **43**(2):223-233, 2006
48. Garcia FU et al: Increased sensitivity of anal cytology in evaluation of internal compared with external lesions. *Acta Cytol* **51**(6):893-899, 2007
49. D'Souza G et al: Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* **356**(19):1944-1956, 2007

50. Chaturvedi AK et al: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin Oncol* **26**(4):612-619, 2008
51. Cameron JE et al: The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. *Sex Transm Dis* **32**(11):703-709, 2005
52. Patel P et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. *Ann Intern Med* **148**(10):728-736, 2008
53. Chaturvedi AK et al: Risk of human papillomavirus-associated cancers among persons with AIDS. *J Natl Cancer Inst* **101**(16):1120-1130, 2009
54. Wieland U et al: Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. *Arch Dermatol* **142**(11):1438-1444, 2006
55. Kreuter A et al: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. *J Invest Dermatol* **128**(8):2078-2083, 2008
56. Nguyen MH et al: Nasal carriage of and infection with *Staphylococcus aureus* in HIV-infected patients. *Ann Intern Med* **130**(3):221-225, 1999
57. Ganesh R et al: Staphylococcal carriage and HIV infection. *Lancet* **2**(8662):558, 1989
58. Skiest D et al: Community-onset methicillin-resistant *Staphylococcus aureus* in an urban HIV clinic. *HIV Med* **7**(6):361-368, 2006
59. van de Laar MJ, Monnet DL, Herida M: Multidrug-resistant methicillin-resistant *Staphylococcus aureus* (MRSA) strain in a men-who-have-sex-with-men (MSM) community in the United States: Comment. *Euro Surveill* **13**(3):8019, 2008
60. Lee NE et al: Risk factors for community-associated methicillin-resistant *Staphylococcus aureus* skin infections among HIV-positive men who have sex with men. *Clin Infect Dis* **40**(10):1529-1534, 2005
61. Tong P, Mutasim DF: Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. *Br J Dermatol* **134**(4):797-800, 1996
62. Saint-Leger E et al: Efficacy of cidofovir in an HIV infected patient with an acyclovir and foscarnet resistant herpes simplex virus infection. *Ann Dermatol Venereol* **128**(6-7):747-749, 2001
63. Lalezari J et al: A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. *J Infect Dis* **176**(4):892-898, 1997
64. Gilbert J, Drehs MM, Weinberg JM: Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. *Arch Dermatol* **137**(8):1015-1017, 2001
65. Nikkels AF et al: Chronic verrucous varicella zoster virus skin lesions: Clinical, histological, molecular and therapeutic aspects. *Clin Exp Dermatol* **24**(5):346-353, 1999
66. Gilson IH et al: Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. *J Am Acad Dermatol* **20**(4):637-642, 1989
67. Lokke Jensen B et al: Atypical varicella-zoster infection in AIDS. *Acta Derm Venereol* **73**(2):123-125, 1993
68. Tappero JW et al: Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. *Clin Microbiol Rev* **8**(3):440-450, 1995
69. Arora A et al: Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. *J Infect Dis* **197**(9):1289-1295, 2008
70. Saint-Leger E et al: Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. *Clin Infect Dis* **33**(12):2061-2067, 2001
71. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. *N Engl J Med* **331**(19):1272-1285, 1994
72. Smith KJ et al: Increased drug reactions in HIV-1-positive patients: A possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). *Clin Exp Dermatol* **22**(3):118-123, 1997
73. Coopman SA et al: Cutaneous disease and drug reactions in HIV infection. *N Engl J Med* **328**(23):1670-1674, 1993
74. Saiag P et al: Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. *J Am Acad Dermatol* **26**(4):567-574, 1992

75. Eliaszewicz M et al: Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. *J Am Acad Dermatol* **47**(1):40-46, 2002
76. Kennedy CA et al: Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: Lack of hematologic toxicity and relationship of side effects to CD4<sup>+</sup> lymphocyte count. *J Infect Dis* **168**(2):314-317, 1993
77. Dolev J, Reyter I, Maurer T: Treatment of recurring cutaneous drug reactions in patients with human immunodeficiency virus 1 infection: A series of 3 cases. *Arch Dermatol* **140**(9):1051-1053, 2004
78. McComsey GA et al: Placebo-controlled trial of prednisone in advanced HIV-1 infection. *AIDS* **15**(3):321-327, 2001
79. Yoshizawa S et al: A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. *Ann Allergy Asthma Immunol* **85**(3):241-244, 2000
80. Warren KJ et al: Nevirapine-associated Stevens-Johnson syndrome. *Lancet* **351**(9102):567, 1998
81. Bourezane Y et al: DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. *Clin Infect Dis* **27**(5):1321-1322, 1998
82. Mallal S et al: Association between presence of HLA-B\*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet* **359**(9308):727-732, 2002
83. Mallal S et al: HLA-B\*5701 screening for hypersensitivity to abacavir. *N Engl J Med* **358**(6):568-579, 2008
84. Ward HA, Russo GG, Shrum J: Cutaneous manifestations of antiretroviral therapy. *J Am Acad Dermatol* **46**(2):284-293, 2002
85. Hadigan C et al: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. *Clin Infect Dis* **32**(1):130-139, 2001
86. Thiebaut R et al: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficiency Acquis en Aquitaine. *Clin Infect Dis* **31**(6):1482-1487, 2000
87. Miller J et al: HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. *HIV Med* **4**(3):293-301, 2003
88. Pullinger CR et al: Metabolic Abnormalities and Coronary Heart Disease Risk in Human Immunodeficiency Virus-Infected Adults. *Metab Syndr Relat Disord* 2010
89. Carr A et al: Abacavir substitution for nucleoside analogs in patients with HIV lipodystrophy: A randomized trial. *JAMA* **288**(2):207-215, 2002
90. Tebas P et al: Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS clinical trial group 5125s). *J Acquir Immune Defic Syndr* **45**(2):193-200, 2007
91. Hadigan C et al: Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. *Ann Intern Med* **140**(10):786-794, 2004
92. Lipscombe LL et al: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. *JAMA* **298**(22):2634-2643, 2007
93. Burgess CM, Quiroga RM: Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipodystrophy. *J Am Acad Dermatol* **52**(2):233-239, 2005
94. Silvers SL et al: Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipodystrophy: One-year durability. *Plast Reconstr Surg* **118**(3 Suppl):345-455, 2006
95. Goedert JJ et al: Spectrum of AIDS-associated malignant disorders. *Lancet* **351**(9119):1833-1839, 1998
96. Wilkins K et al: Cutaneous malignancy and human immunodeficiency virus disease. *J Am Acad Dermatol* **54**(2):189-206 quiz 207-110, 2006
97. Crum-Cianflone N et al: Cutaneous malignancies among HIV-infected persons. *Arch Intern Med* **169**(12):1130-1138, 2009
98. Nguyen P et al: Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. *Arch Dermatol* **138**(6):758-763, 2002
99. Sitz KV, Keppen M, Johnson DF: Metastatic basal cell carcinoma in acquired immunodeficiency syndrome-related complex. *JAMA* **257**(3):340-343, 1987
100. Lobo DV et al: Nonmelanoma skin cancers and infection with the human immunodeficiency virus. *Arch Dermatol* **128**(5):623-627, 1992
101. Kagen MH et al: Multiple infundibulocystic basal cell carcinomas in association with human immunodeficiency virus. *J Cutan Pathol* **27**(6):316-318, 2000

102. Engels EA et al: Merkel cell carcinoma and HIV infection. *Lancet* **359**(9305):497-498, 2002
103. Coldiron BM, Bergstresser PR: Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. *Arch Dermatol* **125**(3):357-361, 1989
104. Rodwell GE, Berger TG: Pruritus and cutaneous inflammatory conditions in HIV disease. *Clin Dermatol* **18**(4):479-484, 2000
105. Zancanaro PC et al: Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: An institutional urban clinic experience. *J Am Acad Dermatol* **54**(4):581-588, 2006
106. Fearfield LA et al: Itchy folliculitis and human immunodeficiency virus infection: Clinicopathological and immunological features, pathogenesis and treatment. *Br J Dermatol* **141**(1):3-11, 1999
107. Rosenthal D et al: Human immunodeficiency virus-associated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. *Arch Dermatol* **127**(2):206-209, 1991
108. Berger TG et al: Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. *Arch Dermatol* **131**(3):358-360, 1995
109. Otley CC, Avram MR, Johnson RA: Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Results of an open, pilot trial. *Arch Dermatol* **131**(9):1047-1050, 1995
110. Lim HW et al: UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. *J Am Acad Dermatol* **37**(3 Pt 1):414-417, 1997
111. Gelfand JM et al: Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: A self-controlled prospective study. *Arch Dermatol* **134**(8):940-945, 1998
112. Buchness MR et al: Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome. Treatment with ultraviolet B phototherapy. *N Engl J Med* **318**(18):1183-1186, 1988
113. Colebunders R et al: Generalized papular pruritic eruption in African patients with human immunodeficiency virus infection. *AIDS* **1**(2):117-121, 1987
114. Liautaud B et al: Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. *Arch Dermatol* **125**(5):629-632, 1989
115. Resneck JS Jr et al: Etiology of pruritic papular eruption with HIV infection in Uganda. *JAMA* **292**(21):2614-2621, 2004
116. Vin-Christian K et al: Photosensitivity in HIV-infected individuals. *J Dermatol* **27**(6):361-369, 2000
117. Bilu D et al: Clinical and epidemiologic characterization of photosensitivity in HIV-positive individuals. *Photodermatol Photoimmunol Photomed* **20**(4):175-183, 2004
118. Morar N et al: Erythroderma: A comparison between HIV positive and negative patients. *Int J Dermatol* **38**(12):895-900, 1999
119. Weinert M, Grimes RM, Lynch DP: Oral manifestations of HIV infection. *Ann Intern Med* **125**(6):485-496, 1996
120. Laskaris G, Hadjivassiliou M, Stratigos J: Oral signs and symptoms in 160 Greek HIV-infected patients. *J Oral Pathol Med* **21**(3):120-123, 1992
121. Phelan JA et al: Oral findings in patients with acquired immunodeficiency syndrome. *Oral Surg Oral Med Oral Pathol* **64**(1):50-56, 1987
122. Tappuni AR, Fleming GJ: The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: A UK study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **92**(6):623-628, 2001
123. Husak R, Garbe C, Orfanos CE: Oral hairy leukoplakia in 71 HIV-seropositive patients: Clinical symptoms, relation to immunologic status, and prognostic significance. *J Am Acad Dermatol* **35**(6):928-934, 1996
124. Lozada-Nur F, Costa C: Retrospective findings of the clinical benefits of podophyllum resin 25% sol on hairy leukoplakia. Clinical results in nine patients. *Oral Surg Oral Med Oral Pathol* **73**(5):555-558, 1992
125. Schwartz RA et al: Bacillary angiomatosis: Presentation of six patients, some with unusual features. *Br J Dermatol* **136**(1):60-65, 1997
126. Perkocha LA et al: Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. *N Engl J Med* **323**(23):1581-1586, 1990
127. Stevens DL et al: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis* **41**(10):1373-1406, 2005
128. Terranova M et al: Clinical and epidemiological study of cutaneous tuberculosis in Northern Ethiopia. *Dermatology* **217**(1):89-93, 2008
129. Arianayagam AV, Ash S, Jones RR: Lichen scrofulosorum in a patient with AIDS. *Clin Exp Dermatol* **19**(1):74-76, 1994
130. High WA, Evans CC, Hoang MP: Cutaneous miliary tuberculosis in two patients with HIV infection. *J Am Acad Dermatol* **50**(5 Suppl):S110-S113, 2004

131. Duerr A et al: Immune compromise and prevalence of *Candida vulvovaginitis* in human immunodeficiency virus-infected women. *Obstet Gynecol* **90**(2):252-256, 1997
132. Carpenter CC et al: Human immunodeficiency virus infection in North American women: Experience with 200 cases and a review of the literature. *Medicine (Baltimore)* **70**(5):307-325, 1991
133. Prose NS: HIV infection in children. *J Am Acad Dermatol* **22**(6 Pt 2):1223-1231, 1990
134. Kwon KS et al: Widespread and invasive *Trichophyton rubrum* infection mimicking Kaposi's sarcoma in a patient with AIDS. *J Dermatol* **31**(10):839-843, 2004
135. Johnson RA: Dermatophyte infections in human immune deficiency virus (HIV) disease. *J Am Acad Dermatol* **43**(5 Suppl):S135-S142, 2000
136. Murakawa GJ, Kerschmann R, Berger T: Cutaneous *Cryptococcus* infection and AIDS. Report of 12 cases and review of the literature. *Arch Dermatol* **132**(5):545-548, 1996
137. Dimino-Emme L, Gurevitch AW: Cutaneous manifestations of disseminated cryptococcosis. *J Am Acad Dermatol* **32**(5 Pt 2):844-850, 1995
138. Durden FM, Elewski B: Cutaneous involvement with *Cryptococcus neoformans* in AIDS. *J Am Acad Dermatol* **30**(5 Pt 2):844-848, 1994
139. Venkatesan P, Perfect JR, Myers SA: Evaluation and management of fungal infections in immunocompromised patients. *Dermatol Ther* **18**(1):44-57, 2005
140. Dover JS, Johnson RA: Cutaneous manifestations of human immunodeficiency virus infection. Part II. *Arch Dermatol* **127**(10):1549-1558, 1991
141. Laochumroonvorapong P et al: Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. *Int J Dermatol* **40**(8):518-521, 2001
142. Angius AG et al: Disseminated histoplasmosis presenting with cutaneous lesions in a patient with acquired immunodeficiency syndrome. *J Eur Acad Dermatol Venereol* **10**(2):182-185, 1998
143. Murakawa GJ et al: Cutaneous aspergillosis and acquired immunodeficiency syndrome. *Arch Dermatol* **136**(3):365-369, 2000
144. Singh N, Yu VL, Rihs JD: Invasive aspergillosis in AIDS. *South Med J* **84**(7):822-827, 1991
145. Herbrecht R et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* **347**(6):408-415, 2002
146. Ustianowski AP, Sieu TP, Day JN: *Penicillium marneffei* infection in HIV. *Curr Opin Infect Dis* **21**(1):31-36, 2008
147. Supparatpinyo K et al: Disseminated *Penicillium marneffei* infection in southeast Asia. *Lancet* **344**(8915):110-113, 1994
148. Duong TA: Infection due to *Penicillium marneffei*, an emerging pathogen: Review of 155 reported cases. *Clin Infect Dis* **23**(1):125-130, 1996
149. Supparatpinyo K et al: A controlled trial of itraconazole to prevent relapse of *Penicillium marneffei* infection in patients infected with the human immunodeficiency virus. *N Engl J Med* **339**(24):1739-1743, 1998
150. Hicks CB, Myers SA, Giner J: Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. *Clin Infect Dis* **24**(5):1023-1025, 1997
151. Sen S, Bhaumik P: Resolution of giant Molluscum contagiosum with antiretroviral therapy. *Indian J Dermatol Venereol Leprol* **74**(3):267-268, 2008
152. Strauss RM et al: Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. *Int J STD AIDS* **12**(4):264-266, 2001
153. Buckley R, Smith K: Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. *Arch Dermatol* **135**(10):1167-1169, 1999
154. Toro JR et al: Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. *Arch Dermatol* **136**(8):983-985, 2000
155. Calista D: Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. *J Eur Acad Dermatol Venereol* **14**(6):484-488, 2000
156. Oliveira Mde F et al: Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil. *Clin Infect Dis* **40**(11):e90-e96, 2005
157. Bonamigo RR et al: Human T lymphotropic virus 1 and hepatitis C virus as risk factors for inflammatory dermatoses in HIV-positive patients. *Int J Dermatol* **43**(8):568-570, 2004
158. Schechter M et al: Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. *JAMA* **271**(5):353-357, 1994

159. Roberts LJ et al: Crusted scabies: Clinical and immunological findings in seventy-eight patients and a review of the literature. *J Infect* **50**(5):375-381, 2005
160. Hengge UR et al: Scabies: A ubiquitous neglected skin disease. *Lancet Infect Dis* **6**(12):769-779, 2006
161. Currie BJ, McCarthy JS: Permethrin and ivermectin for scabies. *N Engl J Med* **362**(8):717-725, 2010
162. Alvar J et al: The relationship between leishmaniasis and AIDS: The second 10 years. *Clin Microbiol Rev* **21**(2):334-359, table of contents, 2008
163. Olivier M et al: The pathogenesis of Leishmania/HIV co-infection: Cellular and immunological mechanisms. *Ann Trop Med Parasitol* **97**(Suppl 1):79-98, 2003
164. Couppie P et al: Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. *Br J Dermatol* **151**(6):1165-1171, 2004
165. Dal Maso L et al: Pattern of cancer risk in persons with AIDS in Italy in the HAART era. *Br J Cancer* **100**(5):840-847, 2009

